ABVX Latest Headlines

Abivax Secures $920 Million Through Full Exercise of Underwriters' Option: Funding Fuels Late-Stage IBD Drug Push

Market Chameleon (Thu, 2-Jul 11:44 AM)

Abivax SA Raises $760 Million in Major U.S. ADS Offering

at www.tipranks.com (Thu, 2-Jul 4:27 PM)

Abivax raises $920M as underwriters fully exercise overallotment option

at seekingalpha.com (Thu, 2-Jul 7:06 AM)

Analysts Offer Insights on Healthcare Companies: SCYNEXIS (SCYX) and Abivax SA Sponsored ADR (ABVX)

at www.tipranks.com (Thu, 2-Jul 4:30 AM)

Abivax’s $800M Upsized ADS Offering Priced at Premium: Extended Cash Runway Signals Ambitious US Plans

Market Chameleon (Wed, 1-Jul 8:58 AM)

Abivax SA prices upsized $800M ADS offering

at seekingalpha.com (Wed, 1-Jul 8:56 AM)

Abivax Reports Meaningful Long-Term Efficacy and Safety Results for Obefazimod in Refractory Ulcerative Colitis

Market Chameleon (Tue, 30-Jun 10:29 AM)

Abivax launches $600M underwritten public offering

at seekingalpha.com (Tue, 30-Jun 5:02 PM)

Biggest stock movers Tuesday: Crypto stocks, FCEL, ABVX, and more

at seekingalpha.com (Tue, 30-Jun 10:09 AM)

Wall Street Analysts Are Bullish on Top Healthcare Picks

at www.tipranks.com (Tue, 30-Jun 9:10 AM)

Analysts Offer Insights on Healthcare Companies: Replimune Group (REPL), Abivax SA Sponsored ADR (ABVX) and Larimar Therapeutics (LRMR)

at www.tipranks.com (Tue, 30-Jun 8:10 AM)

Analysts Offer Insights on Healthcare Companies: HeartFlow, Inc. (HTFL), Taysha Gene Therapies (TSHA) and Abivax SA Sponsored ADR (ABVX)

at www.tipranks.com (Tue, 30-Jun 7:20 AM)

At a glance: stocks gapping up premarket

at seekingalpha.com (Tue, 30-Jun 7:12 AM)

Why Is Abivax Stock (ABVX) Up 34% in Pre-Market Today, 6/30/26?

at www.tipranks.com (Tue, 30-Jun 6:01 AM)

Barclays Sticks to Its Buy Rating for Abivax SA Sponsored ADR (ABVX)

at www.tipranks.com (Tue, 30-Jun 5:06 AM)

ABVX Faces Shareholder Investigation as Rare Malignancy Cases Surface in Phase 3 Trial

Market Chameleon (Thu, 4-Jun 11:08 AM)

ABVX Phase 2 Data Draws Spotlight to Chronic Inflammatory Disease Innovation

Market Chameleon (Thu, 28-May 8:40 AM)

Abivax Shareholders Green-Light All Proposals at 2026 Annual General Meeting: Focus Sharpens on Phase 3 Developments

Market Chameleon (Tue, 12-May 9:13 AM)

Abivax Locks in $45M Offering and Retires Royalty Certificates, Extending Cash Runway Into Q4 2027

Market Chameleon (Tue, 5-May 7:08 AM)

Abivax Highlights Comprehensive Obefazimod Data at Upcoming Digestive Disease Week Conference

Market Chameleon (Thu, 23-Apr 8:27 AM)

Abivax Releases Full Preparatory Documents for May 2026 Shareholder Meeting: What Should Investors Watch?

Market Chameleon (Tue, 21-Apr 7:14 AM)